These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27622603)

  • 21. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Therapy in Melanoma.
    Callahan MK
    Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [PD-1 blockade therapy in lymphoid malignancies].
    Nishikori M; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical use of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
    [No Abstract]   [Full Text] [Related]  

  • 28. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are virus-induced cancers more sensitive to checkpoint inhibitors?
    Kanaan H; Kourie HR; Awada AH
    Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting Immune System Alterations in Hodgkin Lymphoma.
    Grover NS; Savoldo B
    Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Checkpoint inhibitors in Hodgkin lymphoma].
    Sasse S; Momotow J; Engert A
    Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
    Campbell MT; Siefker-Radtke AO; Gao J
    Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials.
    Zhang X; Chen L; Zhao Y; Yin H; Ma H; He M
    Biomed Res Int; 2019; 2019():9283860. PubMed ID: 31950058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Development of PD-1 Blockade in Hematologic Malignancies.
    Pianko MJ; Goldberg AD; Lesokhin AM
    Cancer J; 2018; 24(1):31-35. PubMed ID: 29360725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.
    Issa AK; Westin JR
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):483-487. PubMed ID: 27364263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
    Vardhana S; Younes A
    Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targetable molecular pathways in classical Hodgkin's lymphoma.
    Adams H; Obermann EC; Dirnhofer S; Tzankov A
    Expert Opin Investig Drugs; 2011 Feb; 20(2):141-51. PubMed ID: 21204722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.